AP2048A - Diazepinoindole derivatives as kinase inhibitors - Google Patents

Diazepinoindole derivatives as kinase inhibitors

Info

Publication number
AP2048A
AP2048A AP2005003353A AP2005003353A AP2048A AP 2048 A AP2048 A AP 2048A AP 2005003353 A AP2005003353 A AP 2005003353A AP 2005003353 A AP2005003353 A AP 2005003353A AP 2048 A AP2048 A AP 2048A
Authority
AP
ARIPO
Prior art keywords
kinase inhibitors
diazepinoindole
derivatives
diazepinoindole derivatives
kinase
Prior art date
Application number
AP2005003353A
Other languages
English (en)
Other versions
AP2005003353A0 (en
Inventor
Sacha Ninkovic
Michael John Bennett
Eugene Yuanjin Rui
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of AP2005003353A0 publication Critical patent/AP2005003353A0/xx
Application granted granted Critical
Publication of AP2048A publication Critical patent/AP2048A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/06—Peri-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AP2005003353A 2003-01-09 2004-01-05 Diazepinoindole derivatives as kinase inhibitors AP2048A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43939603P 2003-01-09 2003-01-09
PCT/IB2004/000026 WO2004063198A1 (en) 2003-01-09 2004-01-05 Diazepinoindole derivatives as kinase inhibitors

Publications (2)

Publication Number Publication Date
AP2005003353A0 AP2005003353A0 (en) 2005-09-30
AP2048A true AP2048A (en) 2009-09-24

Family

ID=32713475

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2005003353A AP2048A (en) 2003-01-09 2004-01-05 Diazepinoindole derivatives as kinase inhibitors

Country Status (34)

Country Link
US (3) US6967198B2 (de)
EP (2) EP1585749B1 (de)
JP (1) JP3990718B2 (de)
KR (1) KR100697746B1 (de)
CN (1) CN1759118B (de)
AP (1) AP2048A (de)
AT (1) ATE404564T1 (de)
AU (1) AU2004203977B2 (de)
BR (1) BRPI0406701A (de)
CA (1) CA2512683C (de)
CR (1) CR7899A (de)
CY (1) CY1108408T1 (de)
DE (1) DE602004015724D1 (de)
DK (1) DK1585749T3 (de)
EA (1) EA009337B1 (de)
EC (1) ECSP055911A (de)
ES (1) ES2309484T3 (de)
GE (1) GEP20084367B (de)
HR (1) HRP20050624A2 (de)
IL (1) IL169082A (de)
IS (1) IS7884A (de)
MA (1) MA27703A1 (de)
MX (1) MXPA05007352A (de)
NO (1) NO20053775L (de)
NZ (1) NZ540638A (de)
OA (1) OA13017A (de)
PL (1) PL378372A1 (de)
PT (1) PT1585749E (de)
RS (1) RS20050522A (de)
SI (1) SI1585749T1 (de)
TN (1) TNSN05176A1 (de)
UA (1) UA80733C2 (de)
WO (1) WO2004063198A1 (de)
ZA (1) ZA200504674B (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2473886C (en) * 2002-01-22 2012-08-21 The Regents Of The University Of California Non-steroidal ligands for the glucocorticoid receptor, compositions and uses thereof
EA009337B1 (ru) * 2003-01-09 2007-12-28 Пфайзер Инк. Трициклические соединения, представляющие собой ингибиторы протеинкиназ, для увеличения эффективности противоопухолевых агентов и лучевой терапии
JP2008530575A (ja) * 2005-02-18 2008-08-07 アストラゼネカ アクチボラグ Ｃｈｋ１阻害薬に対する応答性を判定する方法
JP5117374B2 (ja) 2005-03-29 2013-01-16 イコス・コーポレイション Ｃｈｋ１阻害に有用なヘテロアリール尿素誘導体
GB0510390D0 (en) * 2005-05-20 2005-06-29 Novartis Ag Organic compounds
ZA200800314B (en) 2005-06-29 2009-09-30 Threshold Pharmaceuticals Inc Phosphoramidate alkylator prodrugs
AU2006279541A1 (en) 2005-08-15 2007-02-22 The Regents Of The University Of California VEGF-activated FAS ligands
WO2007023948A1 (ja) 2005-08-25 2007-03-01 Ube Industries, Ltd. 光学活性（Ｓ又はＲ）－α－アミノ酸及び光学活性（Ｒ又はＳ）－α－アミノ酸エステルの製造方法
EP1916896A4 (de) * 2005-08-26 2010-08-11 Univ California Nichtsteroid-antiandrogene
CN101415417A (zh) * 2006-04-04 2009-04-22 辉瑞产品公司 (2r,z)-2-氨基-2-环己基-n-(5-(1-甲基-1h-吡唑-4-基)-1-氧代-2,6-二氢-1h-[1,2]二氮杂卓并[4,5,6-cd]吲哚-8-基)乙酰胺的组合疗法
WO2007113647A1 (en) * 2006-04-04 2007-10-11 Pfizer Products Inc. Polymorphic forms of (2r,z)-2-amino-2-cyclohexyl-n-(5-(1-methyl-1h-pyrazol-4υl)-1-oxo-2,6-dihydro-1h-[1,2]diazepino[4,5,6-cd]indol-8-yl)acetamide
EP2086644A2 (de) * 2006-11-17 2009-08-12 Schering Corporation Kombination aus einem hemmer der dna-polymerase-alpha und einem hemmer der checkpointkinase zur behandlung von proliferativen erkrankungen
US8158656B2 (en) * 2008-05-16 2012-04-17 Shenzhen Chipscreen Biosciences Ltd. 2-indolinone derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors
JP5576370B2 (ja) * 2008-08-06 2014-08-20 ファイザー・インク Ｃｈｋ−１阻害剤としての６置換２−ヘテロシクリルアミノピラジン化合物
EP2346881A1 (de) * 2008-10-10 2011-07-27 Priaxon AG Neue verbindungen, die die kinaseaktivität modulieren
US8314108B2 (en) 2008-12-17 2012-11-20 Eli Lilly And Company 5-(5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-ylamino)pyrazine-2-carbonitrile, pharmaceutically acceptable salts thereof, or solvate of salts
US8663210B2 (en) 2009-05-13 2014-03-04 Novian Health, Inc. Methods and apparatus for performing interstitial laser therapy and interstitial brachytherapy
US8211901B2 (en) 2009-05-22 2012-07-03 Shenzhen Chipscreen Biosciences Ltd. Naphthamide derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors
CN101906076B (zh) 2009-06-04 2013-03-13 深圳微芯生物科技有限责任公司 作为蛋白激酶抑制剂和组蛋白去乙酰化酶抑制剂的萘酰胺衍生物、其制备方法及应用
AU2012253759B2 (en) 2011-05-06 2016-01-21 Zafgen Inc. Tricyclic sulfonamide compounds and methods of making and using same
EP2793882A4 (de) 2011-12-22 2015-04-29 Threshold Pharmaceuticals Inc Verabreichung von hypoxie-aktivierten prodrugs in kombination mit chk1-inhibitoren zur behandlung von krebs
KR101716012B1 (ko) * 2011-12-31 2017-03-13 베이진 엘티디 Parp 저해제로서의 융합된 테트라 또는 펜타-사이클릭 다이하이드로다이아제피노카르바졸론
KR101684039B1 (ko) 2011-12-31 2016-12-07 베이진 엘티디 Parp 저해제로서의 융합된 테트라 또는 펜타-사이클릭 피리도프탈라지논
CN102746211B (zh) * 2012-06-27 2015-05-27 上海泰坦化学有限公司 一种取代吲哚-3-甲醛类化合物的制备方法
TWI633107B (zh) * 2013-05-22 2018-08-21 開曼群島商百濟神州生物科技有限公司 作為ｐａｒｐ抑制劑的稠合四或五環二氫二氮呯并咔唑酮
AU2014293013A1 (en) 2013-07-26 2016-03-17 Race Oncology Ltd. Combinatorial methods to improve the therapeutic benefit of bisantrene
US10071109B2 (en) 2013-11-06 2018-09-11 Molecular Templates, Inc. Predictive biomarker for hypoxia-activated prodrug therapy
US11179394B2 (en) 2014-06-17 2021-11-23 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of Chk1 and ATR inhibitors
AU2016312011B2 (en) * 2015-08-25 2021-02-04 Beigene, Ltd. Process for preparing Parp inhibitor, crystalline forms, and uses thereof
US11464774B2 (en) 2015-09-30 2022-10-11 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors
US11202782B2 (en) 2016-09-27 2021-12-21 Beigene, Ltd. Treatment cancers using a combination comprising PARP inhibitors
JP6541635B2 (ja) * 2016-10-28 2019-07-10 ベイジーン リミテッド Ｐａｒｐ阻害剤としての縮合四環式または縮合五環式ジヒドロジアゼピノカルバゾロン
CN110392687B (zh) 2017-02-28 2022-08-02 百济神州(苏州)生物科技有限公司 稠合的四环或五环二氢二氮杂䓬并咔唑酮的盐的结晶形式及其用途
US11661581B2 (en) * 2017-05-25 2023-05-30 University Of Massachusetts Use of CDK inhibitors to enhance growth and self-renewal of progenitor cells
RU2764243C2 (ru) * 2017-09-22 2022-01-14 ДЖУБИЛАНТ ЭПИПЭД ЭлЭлСи Гетероциклические соединения в качестве ингибиторов PAD
EP3461480A1 (de) 2017-09-27 2019-04-03 Onxeo Kombination von checkpoint-hemmern des dna-schädigungsantwort-zellzyklus und belinostat zur behandlung von krebs
EP3914284A4 (de) * 2019-01-25 2022-10-26 Numedii, Inc. Verfahren zur behandlung von idiopathischer lungenfibrose
CN114072410B (zh) * 2019-08-01 2023-08-01 正大天晴药业集团股份有限公司 作为parp抑制剂吲哚并七元酰肟化合物
EP4067351B1 (de) 2019-11-29 2025-01-22 NovaOnco JS Therapeutics Co., Ltd. Diazaindolderivate und ihre verwendung als chk1-inhibitoren
WO2022011458A1 (en) * 2020-07-13 2022-01-20 Ontario Institute For Cancer Research (Oicr) Nicotinamide phosphoribosyltransferase (nampt) inhibitor-conjugates and uses thereof
AU2021318572A1 (en) * 2020-07-31 2023-02-16 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Indolo heptamyl oxime analog crystal as PARP inhibitor and method for preparing same

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000042040A1 (en) * 1999-01-11 2000-07-20 Agouron Pharmaceuticals, Inc. Tricyclic inhibitors of poly(adp-ribose) polymerases
WO2002044183A2 (en) * 2000-12-01 2002-06-06 Guilford Pharmaceuticals Inc. Benzoazepine and benzodiazepine derivatives and their use as parp inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9722320D0 (en) 1997-10-22 1997-12-17 Janssen Pharmaceutica Nv Human cell cycle checkpoint proteins
US6383744B1 (en) 1998-07-10 2002-05-07 Incyte Genomics, Inc. Human checkpoint kinase
EP1135135A4 (de) 1998-09-18 2006-08-09 Smithkline Beecham Corp Chk1 kinase inhibitoren
JP4652648B2 (ja) 1999-08-27 2011-03-16 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド キメラアンチセンスオリゴヌクレオチド、およびその細胞トランスフェクション処方物
ECSP003637A (es) 1999-08-31 2002-03-25 Agouron Pharma Inhibidores triciclicos de poli (adp-ribosa) polimerasas
US6670167B1 (en) 1999-11-01 2003-12-30 Agouron Pharmaceuticals, Inc. Catalytic domain of the human effector cell cycle checkpoint protein kinase materials and methods for identification of inhibitors thereof
DE60019318T2 (de) 1999-09-22 2006-03-09 Canbas Co., Ltd., Numazu Zusammensetzungen und verfahren zur inhibierung vom zellulären g2-übergang und sensitisierung von zellen gegen dna-schädigenden wirkstoffe
US6211164B1 (en) 2000-03-10 2001-04-03 Abbott Laboratories Antisense oligonucleotides of the human chk1 gene and uses thereof
UA76977C2 (en) 2001-03-02 2006-10-16 Icos Corp Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers
EA009337B1 (ru) * 2003-01-09 2007-12-28 Пфайзер Инк. Трициклические соединения, представляющие собой ингибиторы протеинкиназ, для увеличения эффективности противоопухолевых агентов и лучевой терапии

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000042040A1 (en) * 1999-01-11 2000-07-20 Agouron Pharmaceuticals, Inc. Tricyclic inhibitors of poly(adp-ribose) polymerases
WO2002044183A2 (en) * 2000-12-01 2002-06-06 Guilford Pharmaceuticals Inc. Benzoazepine and benzodiazepine derivatives and their use as parp inhibitors

Also Published As

Publication number Publication date
MA27703A1 (fr) 2006-01-02
TNSN05176A1 (fr) 2007-06-11
UA80733C2 (en) 2007-10-25
WO2004063198A1 (en) 2004-07-29
JP2006516274A (ja) 2006-06-29
EP1947102A1 (de) 2008-07-23
NZ540638A (en) 2007-12-21
PT1585749E (pt) 2008-10-23
NO20053775L (no) 2005-09-16
NO20053775D0 (no) 2005-08-08
GEP20084367B (en) 2008-05-13
JP3990718B2 (ja) 2007-10-17
EA200500893A1 (ru) 2006-02-24
CN1759118A (zh) 2006-04-12
US6967198B2 (en) 2005-11-22
US7462713B2 (en) 2008-12-09
KR20050092397A (ko) 2005-09-21
EP1585749A1 (de) 2005-10-19
ECSP055911A (es) 2005-11-22
SI1585749T1 (sl) 2008-10-31
CR7899A (es) 2005-08-05
AP2005003353A0 (en) 2005-09-30
ATE404564T1 (de) 2008-08-15
US20050075499A1 (en) 2005-04-07
PL378372A1 (pl) 2006-04-03
US20070135415A1 (en) 2007-06-14
US20060004052A1 (en) 2006-01-05
DE602004015724D1 (de) 2008-09-25
EA009337B1 (ru) 2007-12-28
CY1108408T1 (el) 2014-02-12
DK1585749T3 (da) 2008-09-22
CN1759118B (zh) 2010-12-08
CA2512683A1 (en) 2004-07-29
ZA200504674B (en) 2006-07-26
IL169082A (en) 2011-02-28
US7132533B2 (en) 2006-11-07
ES2309484T3 (es) 2008-12-16
OA13017A (en) 2006-11-10
CA2512683C (en) 2010-03-16
MXPA05007352A (es) 2006-02-17
IS7884A (is) 2005-06-09
HRP20050624A2 (en) 2006-02-28
HK1086257A1 (en) 2006-09-15
AU2004203977A1 (en) 2004-07-29
EP1585749B1 (de) 2008-08-13
RS20050522A (sr) 2007-12-31
BRPI0406701A (pt) 2005-12-20
KR100697746B1 (ko) 2007-03-22
AU2004203977B2 (en) 2010-06-17

Similar Documents

Publication Publication Date Title
PT1585749E (pt) Derivados de diazepinoindole como inibidores de cinase
IL165515A0 (en) Bisindolyl-maleimid derivatives as kinase inhibitors
IL172132A0 (en) Thienopyridone derivatives as kinase inhibitors
IL173381A0 (en) 2-aminophenyl-4-phenylpyrimidines as kinase inhibitors
IL173380A0 (en) Pyridinylamino-pyrimidine derivatives as protein kinase inhibitors
AU2003271566A8 (en) Pyrrolopyrazines as kinase inhibitors
IL173200A0 (en) Piperidyl-quinazoline derivatives as tyrosine kinase inhibitors
PL373649A1 (en) Kinase inhibitors
IL177278A0 (en) Pyrazolotriazines as kinase inhibitors
ZA200702394B (en) Indozolone derivatives as 11b-HSD1 inhibitors
ZA200700181B (en) Aryl-pyridine derivatives as 11-beta-HSD1 inhibitors
SI1569907T1 (sl) Na nikotinamidu osnovani kinazni inhibitorji
IL184674A0 (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
EP1558609A4 (de) Kinase-hemmer
IL172375A0 (en) Chinazoline derivatives as aurora kinase inhibitors
GB2423083B (en) Azole-based kinase inhibitors
AU2003254051A8 (en) Pyrazolopyrimidines as kinase inhibitors
PL378116A1 (pl) Heterocykliczne inhibitory kinazy
EP1812424A4 (de) Kinase-inhibitoren
EP1569907A4 (de) Nicotinamid-basierte kinasehemmer
EP1778693A4 (de) Als kinaseinhibitoren nützliche verbindungen von trizyklischem heteroaryl
ZA200703835B (en) Heterocyclic substituted bisarylurea derivatives as kinase inhibitors
AU2003232362A8 (en) 4-pyrazol-phenylalanine derivatives as ace-nep inhibitors
HK1086560A (en) Thienopyridone derivatives as kinase inhibitors
SI1483265T1 (sl) Drivati purina kot inhibitoriji kinaze